Discontinue Lantus and Maximize Oral Agents with Close Monitoring
For this homeless patient unable to store insulin, discontinue the Lantus 10 units daily and intensify the oral regimen by increasing sitagliptin to 100 mg daily while continuing dapagliflozin 5 mg daily, with metformin added if not contraindicated. This patient's blood glucose range of 123-344 mg/dL indicates inadequate control that requires medication intensification, not just insulin discontinuation 1.
Rationale for Insulin Discontinuation
The patient is on a very low dose of basal insulin (10 units daily, likely <0.15 U/kg), which suggests either early insulin requirement or poor baseline control. Given the social circumstances preventing insulin storage in the shelter, continuing insulin poses both practical impossibility and safety risks 1.
Recommended Oral Regimen
Immediate Changes:
Increase sitagliptin from 25 mg to 100 mg daily - The current 25 mg dose is subtherapeutic. Standard dosing is 100 mg daily, which provides superior glycemic control without hypoglycemia risk 2, 3
Continue dapagliflozin 5 mg daily - This SGLT2 inhibitor provides glucose-lowering without hypoglycemia risk and offers cardiovascular benefits. However, educate the patient about diabetic ketoacidosis warning signs and ensure adequate hydration access, as homelessness increases DKA risk 4, 5
Add metformin 500-1000 mg twice daily (if renal function permits and no contraindications) - Metformin remains first-line therapy and works synergistically with DPP-4 inhibitors and SGLT2 inhibitors 1, 3
Critical Safety Considerations
SGLT2 Inhibitor Precautions in Homeless Patients:
The FDA label explicitly warns to withhold dapagliflozin in situations predisposing to ketoacidosis 4. In homeless patients, specific concerns include:
- Unpredictable food intake - increases DKA risk
- Limited access to hydration - increases volume depletion risk
- Poor genital hygiene facilities - increases genital mycotic infection risk (9% incidence) 4
- Difficulty recognizing/reporting symptoms - delays treatment of complications
Despite these risks, dapagliflozin can be continued given its efficacy and the patient's current tolerance, but requires explicit counseling about stopping the medication and seeking care if experiencing nausea, vomiting, abdominal pain, or decreased oral intake 4, 5.
Expected Outcomes
This triple oral combination (metformin + sitagliptin + dapagliflozin) can achieve:
- HbA1c reduction of 1.0-1.5% from baseline 3
- Fasting glucose reduction of 15-30 mg/dL 6, 7
- Weight reduction of 1-2 kg (beneficial given likely obesity) 8, 9
- Minimal hypoglycemia risk (<1% severe hypoglycemia) 1, 3
Monitoring Plan
- Check blood glucose at shelter or clinic weekly initially to assess response
- Target glucose <180 mg/dL fasting, <200 mg/dL postprandial as realistic goals 1
- Reassess in 2-4 weeks - if glucose remains >300 mg/dL consistently, insulin will be unavoidable and alternative housing/storage solutions must be found 1
- Monitor for genital infections, urinary symptoms, and volume depletion given SGLT2 inhibitor use 4
Alternative if Oral Regimen Fails
If blood glucose remains severely elevated (consistently >300 mg/dL) after 2-4 weeks on maximized oral therapy, this patient will require insulin regardless of housing status 1. In this scenario:
- Coordinate with social services for insulin storage solutions (clinic-based administration, day programs, case management)
- Consider once-weekly GLP-1 agonist as alternative injectable if available and affordable
- Basal insulin 0.2-0.3 U/kg daily would be indicated for severe hyperglycemia >300 mg/dL 1
Common Pitfall to Avoid
Do not simply discontinue insulin without intensifying oral agents - this patient's glucose of 344 mg/dL indicates the current regimen (Januvia 25 mg + Farxiga 5 mg) is grossly inadequate. The sitagliptin dose is only 25% of the therapeutic dose, leaving substantial room for oral intensification before accepting uncontrolled hyperglycemia 2, 3.